Objective: Some patients who had carried out long-term continuous ambulatory peritoneal dialysis discontinued the treatment because of progressive peritoneal fibrosis. It has been previously reported that transforming growth factor-β1 (TGF-β1) is one of the factors that induces peritoneal fibrosis. Also, hepatocyte growth factor (HGF) plays a role in the prevention of fibrosis and in inhibiting TGF-β1 production. In this study, we examined the effects of HGF on peritoneal fibrosis by TGF-β1 induced by high concentrations of D-glucose. Design: We transfected a full-length human HGF cDNA in an expression vector into human peritoneal mesothelial cells (HPMCs) using the calcium phosphate method. Transfected HPMCs were cultured with high concentrations of D-glucose solution and co-cultured with fibroblasts using a transwell system. Cell proliferation was determined using the Tetra Color One method. TGF-β1 and HGF protein were measured by enzyme-linked immunosorbent assay. Results: In addition to recombinant HGF, the growth inhibition of HPMCs by high concentration D-glucose or TGF-β1 was significant. By transfecting HGF cDNA into HPMCs, growth inhibition by high concentration D-glucose was completely restored. Furthermore, the production of TGF-β1 was also significantly decreased. Conclusion: These results suggested that exogenous HGF could possibly prevent peritoneal fibrosis.

1.
Thomson NM, Walker RG, Whiteside G, Scott DF, Atkins RC: Continuous ambulatory peritoneal dialysis in the treatment of end-stage renal failure. Proc Eur Dial Transplant Assoc 1979;16:171–177.
[PubMed]
2.
Shohat J, Boner G, Rosenfeld J, Waller A, Iaina A, Eliahou HE: Continuous ambulatory peritoneal dialysis – A new dimension in the treatment of end-stage renal disease. Isr J Med Sci 1982;18:1014–1018.
[PubMed]
3.
Dobbie JW: Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992;12:14–27.
[PubMed]
4.
Pollock CA, Ibels LS, Eckstein RP, Graham JC, Caterson RJ, Mahony JF, et al: Peritoneal morphology on maintenance dialysis. Am J Nephrol 1989;9:198–204.
[PubMed]
5.
Gotloib L, Wajsbrot V, Shostak A, Kushnier R: Morphology of the peritoneum: Effect of peritoneal dialysis. Perit Dial Int 1995;15:S9–S11.
6.
Medcalf JF, Walls J, Pawluczyk IZ, Harris KP: Effects of glucose dialysate on extracellular matrix production by human peritoneal mesothelial cells: The role of TGF-β. Nephrol Dial Transplant 2001;16:1885–1892.
7.
Nagy JA: Peritoneal membrane morphology and function. Kidney Int 1996;50(suppl 56): 2–11.
8.
Leavesley DI, Stanley JM, Faull RJ: Epidermal growth factor modifies the expression and function of extracellular matrix adhesion receptors expressed by peritoneal mesothelial cells from patients on CAPD. Nephrol Dial Transplant 1999;14:1208–1216.
9.
Krediet RT, Ho-Dac-Pannekeet MM, Struijk DG: Preservation of peritoneal membrane function. Kidney Int 1996;56(suppl):62–68.
10.
Pollock CA, Ibels LS, Hallett MD, Cocksedge B, Caterson RJ, Mahony JF, et al: Loss of ultrafiltration in continuous ambulatory peritoneal dialysis. Perit Dial Int 1989;9:107–110.
[PubMed]
11.
Finkelstein FO, Sorkin M, Cramton CW, Nolph K: Initiatives in peritoneal dialysis: Where do we go from here? Perit Dial Int 1991;11:274–278.
[PubMed]
12.
Honda K, Nitta K, Horita S, et al: Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996;72:171–176.
[PubMed]
13.
Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS: Dipyridamole inhibits TGF-β-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int 2001;60:1249–1257.
[PubMed]
14.
Gambaro G, Weigert C, Ceol M, Schleicher ED: Inhibition of transforming growth factor-β1 gene overexpression as a strategy to prevent fibrosis. Contrib Nephrol. Basel, Karger, 2001, vol 131, pp 107–113.
15.
Lin CY, Chen WP, Fu LW, Yang LY, Huang TP: Persistent transforming growth factor-β1 expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence. Adv Perit Dial 1997;13:64–71.
[PubMed]
16.
Roberts AB, McCune BK, Sporn MB: TGF-β: Regulation of extracellular matrix. Kidney Int 1992;41:557–559.
[PubMed]
17.
Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 1992;41:107–114.
[PubMed]
18.
Phillips AO, Steadman R, Topley N: Elevated D-glucose concentrations modulate TGF-β1 synthesis by human cultured renal proximal tubular cells. The permissive role of platelet-derived growth factor. Am J Pathol 1995;147:362–374.
[PubMed]
19.
Jong HO, Hunjoo HA, Hi BL: Sequential effects of high glucose on mesangial cell transforming growth factor-β1 and fibronectin synthesis. Kidney Int 1998;54:1872–1878.
20.
Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y, et al: Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int 1996;49:1120–1126.
[PubMed]
21.
Naiki Y, Maeda Y, Matsuo K, Yonekawa S, Sakaguchi M, Iwamoto I, et al: Involvement of TGF-β signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol 2003;16:95–102.
22.
Wang T, Ghen YG, Ye RG, Mai WY, Zhen ZH, Li HQ: Enhanced expression of TGF-β1 by peritoneal macrophages in CAPD patients. Adv Perit Dial 1995;11:11–14.
[PubMed]
23.
Matsumoto K, Nakamura T: Hepatocyte growth factor as a tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 1997;239:639–644.
24.
Michalopoulos GK, Bowen W, Nussler AK, Becich MJ, Howard TA: Comparative analysis of mitogenic and morphogenic effects of HGF and EGF on rat and human hepatocytes maintained in collagen gels. J Cell Physiol 1993;156:443–452.
25.
Yo Y, Morishita R, Nakamura S, Tomita N, Yamamoto K, Moriguchi A, et al: Potential role of hepatocyte growth factor in the maintenance of renal structure: Anti-apoptotic action of HGF on epithelial cells. Kidney Int 1998;54:1128–1138.
26.
Mizuno S, Matsumoto K, Kurosawa T, Mizuno-Horikawa Y, Nakamura T: Reciprocal balance of hepatocyte growth factor and transforming growth factor-β1 in renal fibrosis in mice. Kidney Int 2000;57:937–948.
27.
Mizuno S, Matsumoto K, Nakamura T: Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 2001;59:1304–1314.
28.
Fang JW, Bird GL, Nakamura T, Davis GL, Lau JY: Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis. Lancet 1994;343:820–823.
29.
Dohi M, Hasegawa T, Yamamoto K, Marshall BC: Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000;162:2302–2307.
[PubMed]
30.
Taniyama Y, Morishita R, Aoki M, Hiraoka K, Yamasaki K, Hashiya N, et al: Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 2002;40:47–53.
31.
Oe S, Fukunaka Y, Hirose T, Yamaoka Y, Tabata Y: A trial on regeneration therapy of rat liver cirrhosis by controlled release of hepatocyte growth factor. J Control Release 2003;88:193–200.
32.
Matsumoto K, Nakamura T: Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases. Kidney Int 2001;59:2023–2038.
[PubMed]
33.
Dohi M, Hasegawa T, Yamamoto K, Marshall BC: Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000;162:2302–2307.
[PubMed]
34.
Stylianous E, Lenner LA, Davies M: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990;37:1563–1570.
[PubMed]
35.
Jorres A, Ludat K, Lang J, Sander K, Gahl GM, Frei U, DeJonge K, Williams JD, Topley N: Establishment and functional characterization of human peritoneal fibroblast in culture: Regulation of interleukin-6 production by proinflammatory cytokines. J Am Soc Nephrol 1996;7:2192–2201.
[PubMed]
36.
Ishiyama K, Hayakawa T, Yamaya T: Expression of NADH-dependent glutamate synthase protein in the epidermis and exodermis of rice roots in response to the supply of ammonium ions. Planta 1998;204:288–294.
37.
Ishiyama M, Miyazono Y: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 1997;44:1299–1305.
38.
Tsuboniwa N, Morishita R, Hirano T, Fujimoto J, Furukawa S, Kikumori M, et al: Safety evaluation of hemagglutinating virus of Japan – Artificial viral envelope liposomes in non-human primates. Hum Gene Ther 2001;12:469–487.
39.
Chen C, Okayama H: Calcium phosphate-mediated gene transfer: A highly efficient system for stably transforming cells with plasmid DNA. BioTechniques 1998;6:632–638.
[PubMed]
40.
Frederick M: Current Protocols in Molecular Biology. Toronto, Wiley, 1998, vol 1, chapt 9, pp 1–9.
41.
Kumano K, Shimoda M, Hyodo T, Sakai T: The role of TGF-β in growth inhibition of peritoneal mesothelial cells in high-glucose dialysate. Perit Dial Int 1995;15(suppl 7):93–95.
42.
Van Bronswijk H, Verbrugh HA, Bos HJ, Heezius EC, Oe PL, van der Meulen J, et al: Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis fluids and of bacterial exoproducts on human mesothelial cells in vitro. Perit Dial Int 1989;9:197–202.
[PubMed]
43.
Topley N, Mackenzie R, Petersen MM, Beavis MJ, Williams D, Thomas N, et al: In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant 1991;6:574–581.
[PubMed]
44.
Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12:2434–2441.
[PubMed]
45.
Hatanaka M: Saturable and non-saturable process of sugar uptake: Effect of oncogenic transformation in transport and uptake of nutrients. J Cell Physiol 1976;89:745–750.
46.
Breborowicz A, Rodela H, Oreopoulos DG: Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 1992;41:1280–1285.
[PubMed]
47.
Seki T, Hagiya M, Shimonishi O, Nakamura T, Shimizu S: Organization of the human hepatocyte growth factor-encoding gene. Gene 1991;102:213–219.
48.
Miyazawa K, Kitamura A, Kitamura N: Structural organization and the transcriptional initiation site of the human hepatocyte growth factor gene. Biochemistry 1991;30:9170–9176.
49.
Okajima A, Miyazawa K, Kitamura N: Characterization of the promotor region of the rat hepatocyte growth factor/scatter factor gene. Eur J Biochem 1993;213:113–119.
50.
Rampino T, Cancarini G, Gregorini M, Guallini P, Maggio M, Ranghino A, et al: Hepatocyte growth factor/scatter factor released during peritonitis is active on mesothelial cells. Am J Pathol 2001;159:1275–1285.
[PubMed]
51.
Gao X, Mae H, Ayabe N, Oshima K, Hattori M, Ueki T, et al: Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Kidney Int 2002;62:1238–1248.
52.
Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226–230.
You do not currently have access to this content.